• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Eyenovia Inc.

    3/5/25 5:10:39 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EYEN alert in real time by email
    S-8 1 tm254566d1_s8.htm FORM S-8

      

    As filed with the Securities and Exchange Commission on March 5, 2025

    Registration No. 333-_____

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

    EYENOVIA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   47-1178401
    (State or other jurisdiction of incorporation or
    organization)
      (I.R.S. Employer Identification No.)
         
    23461 S. Pointe Drive, Suite 390    
    Laguna Hills, CA 92653   10017
    (Address of Principal Executive Offices)   (Zip Code)

     

    Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan, as Amended

    (Full title of the plan)

     

    Michael Rowe

    Chief Executive Officer

    23461 S. Pointe Drive, Suite 390

    Laguna Hills, CA 92653

    (833) 393-6684

    (Name, address and telephone number, including area code, of agent for service)

     

    Copy:

     

    Megan N. Gates

    Julie M. Plyler

    Covington & Burling LLP

    1 International Place

    Boston, MA 02110

    (212) 841-1247

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting companyx
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement registers an aggregate of 350,000 additional shares of common stock, par value $0.0001 per share (“Common Stock”), of Eyenovia, Inc. (the “Company” or the “Registrant”) under the Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan, as amended, representing an increase in the number of shares of Common Stock reserved for issuance under such plan as a result of an amendment thereto, which was adopted by the board of directors of the Company on December 3, 2024 and approved by the Company’s stockholders at the Special Meeting of Stockholders held on January 21, 2025.

     

    Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended, the contents of the Registrant’s Registration Statements on Form S-8 filed with the U.S. Securities and Exchange Commission (the “Commission”) on August 27, 2018 (File No. 333-227049), August 14, 2019 (File No. 333-233280), August 14, 2020 (File No. 333-246288), November 12, 2021 (File No. 333-261035), August 12, 2022 (File No. 333-266823) and June 27, 2023 (File No. 333-272962) are incorporated by reference and made part of this Registration Statement. Any items in such registration statements not expressly changed hereby shall be as set forth in such registration statements.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Company is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) and in accordance therewith files reports, proxy statements and other information with the Commission. The following documents, which are on file with the Commission, are incorporated in this Registration Statement by reference:

     

    (a) The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 18, 2024 (File No. 001-38365), as amended by the Company’s Amendment No. 1 to Annual Report on Form 10-K, filed with the Commission on April 26, 2024;

     

    (b) All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the document referred to in (a) above (other than the portions of those documents not deemed to be filed); and

     

    (c) The description of the Company’s Common Stock contained in Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on March 31, 2023 (File No. 001-38365).

     

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit No. Description
       
    4.1 Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on January 29, 2018).
       
    4.2 Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1.1 of the Registrant’s Current Report on Form 8-K filed on June 14, 2018).
       
    4.3 Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on June 14, 2024).
       
    4.4 Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on January 31, 2025).
       
    4.5 Second Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on February 7, 2022).
       
    4.6 Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan, as Amended (incorporated herein by reference to Appendix C of the Registrant’s Proxy Statement on Schedule 14A, filed on December 23, 2024).
       
    5.1* Opinion of Covington and Burling LLP.
       
    23.1* Consent of Marcum LLP.
       
    23.2* Consent of Covington and Burling LLP (included in Exhibit 5.1).
       
    24.1* Power of Attorney (included on the signature page of this Registration Statement).
       
    107* Filing Fees Exhibit.

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Laguna Hills, State of California, on March 5, 2025.

     

      EYENOVIA, INC.
       
      By: /s/ Michael Rowe
        Michael Rowe
        Chief Executive Officer

     

    SIGNATURES AND POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Michael Rowe as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Michael Rowe   Chief Executive Officer
    (Principal Executive Officer) and Director
      March 5, 2025
    Michael Rowe
             
    /s/ Michael Rowe   Principal Financial Officer
    (Principal Financial and Accounting Officer)
      March 5, 2025
    Michael Rowe
     
    /s/ Tsontcho Ianchulev   Director   March 5, 2025
    Tsontcho Ianchulev
             
    /s/ Rachel Jacobson   Director   March 5, 2025
    Rachel Jacobson
             
    /s/ Charles E. Mather IV   Director   March 5, 2025
    Charles E. Mather IV
             
    /s/ Ram Palanki   Director   March 5, 2025
    Ram Palanki
             
    /s/ Michael Geltzeiler   Director   March 5, 2025
    Michael Geltzeiler        
             
    /s/ Ellen R. Strahlman   Director   March 5, 2025
    Ellen R. Strahlman

     

     

    Get the next $EYEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYEN

    DatePrice TargetRatingAnalyst
    11/18/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $EYEN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MYDCOMBI issued to EYENOVIA INC.

    Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/8/23 1:05:04 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Jung Hyunsu was granted 500,000 shares (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    7/9/25 4:04:50 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jacobson Rachel was granted 5,000 shares, increasing direct ownership by 384% to 6,301 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    7/9/25 4:04:18 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rowe Michael M was granted 6,600 shares, increasing direct ownership by 480% to 7,975 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    7/9/25 4:03:45 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    SEC Filings

    View All

    SEC Form PRE 14A filed by Eyenovia Inc.

    PRE 14A - HYPERION DEFI, INC. (0001682639) (Filer)

    7/11/25 8:26:03 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Eyenovia Inc.

    SCHEDULE 13D/A - HYPERION DEFI, INC. (0001682639) (Subject)

    7/2/25 4:49:54 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    7/2/25 4:16:10 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $EYEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $EYEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.

    Name change reflects company's leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol "HYPD" effective July 3rd Also announces official launch of the Kinetiq x Hyperion validator LAGUNA HILLS, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it is rebranding and changing its corporate name to Hyperion DeFi, Inc. Concurrent with the name change, the Company's

    7/2/25 8:00:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement

    LAGUNA HILLS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it has acquired an additional 265,872 HYPE tokens, expanding its total holdings to 1,306,452 HYPE purchased at an average price of $34.83 per token. "We continue to see strong signals from the market and prospective partners affirming the importance of HYPE's role in next-generation financial infrastructure," said Hyunsu Jung, Chief Investment Officer of Eyenovia. "This latest token acq

    6/30/25 8:00:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Announces Co-Branded Validator with Kinetiq

    LAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced a co-branded Hyperliquid validator with Kinetiq, a leading liquid staking protocol built natively for the Hyperliquid ecosystem.  The validator marks a significant step in Eyenovia's onchain engagement strategy, utilizing its recent acquisition of 1,040,584.5 HYPE to contribute directly to network stability and security. Validator operations are further supported by infrastructure provided by Pier

    6/25/25 8:30:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Eyenovia from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

    11/18/24 7:44:30 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Eyenovia with a new price target

    HC Wainwright & Co. reiterated coverage of Eyenovia with a rating of Buy and set a new price target of $8.00 from $6.00 previously

    4/1/21 6:45:58 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Northland Capital initiated coverage on Eyenovia with a new price target

    Northland Capital initiated coverage of Eyenovia with a rating of Outperform and set a new price target of $10.00

    3/1/21 9:11:48 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rowe Michael M bought $14,077 worth of shares (27,071 units at $0.52), increasing direct ownership by 33% to 109,998 units (SEC Form 4)

    4 - EYENOVIA, INC. (0001682639) (Issuer)

    8/28/24 8:01:36 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rowe Michael M bought $28,500 worth of shares (50,000 units at $0.57), increasing direct ownership by 152% to 82,927 units (SEC Form 4)

    4 - EYENOVIA, INC. (0001682639) (Issuer)

    8/27/24 1:06:37 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Grant Stuart M. bought $1,000,000 worth of shares (1,515,151 units at $0.66), increasing direct ownership by 16% to 10,914,153 units (SEC Form 4)

    4 - EYENOVIA, INC. (0001682639) (Issuer)

    7/3/24 3:18:06 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    Financials

    Live finance-specific insights

    View All

    Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of Mydcombi in its second generation Optejet device Announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05% for the treatment of inflammation and pain following ocular surgery Appointed Andrew Jones as Chief Financial Officer Company to host conference call and webcast today, November 12th, at 4:30 pm ET NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing and commercializing adv

    11/12/24 4:05:00 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

    NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that the Company will release financial results for the third quarter ended September 30, 2024 on Tuesday, November 12th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and reference Conference ID# 13748714. To access t

    11/7/24 7:00:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for analysis in Q4 Commenced sales activities with focus on Mydcombi in 260+ offices and preparations for launch of clobetasol propionate ophthalmic suspension 0.05%, the first new ophthalmic steroid to enter the market in 15 years Announced development collaborations with Formosa, Senju and SGN to leverage the Optejet for the $5 billion global dry eye disease market Company to host conference call and webcast today, August 12th, a

    8/12/24 4:05:00 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

    SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

    12/4/24 4:12:20 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eyenovia Inc.

    SC 13G/A - EYENOVIA, INC. (0001682639) (Subject)

    11/14/24 5:08:44 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

    SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

    7/18/24 7:46:49 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EYEN
    Leadership Updates

    Live Leadership Updates

    View All

    Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group

    LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced several key developments in support of its digital asset capital strategy. Avenue Capital Group, now the Company's largest common stockholder, has agreed to amend Eyenovia's senior secured debt to further support the Company as it builds its HYPE treasury and reserve of the HYPE token. Pursuant to the terms of the amendment, the maturity date of the debt has been extended from November 1, 2025 to

    6/18/25 8:32:42 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

    NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced the appointment of experienced finance and accounting executive Andrew Jones as Chief Financial Officer. Mr. Jones brings to the Eyenovia team more than 30 years of diverse finance and accounting leadership experience spanning therapeutics and medical technology/devices, most recently serving as Chief Financial Officer of NovaBay Pharmaceuticals, Inc., a publicly traded, commercial stage ophthalmic company. Eyenovia's current CFO, John Gandolfo, is retiring and will remain with

    9/3/24 7:00:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

    NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the Company's new Chief Executive Officer, effective August 1, 2022. Mr. Rowe's appointment follows the company's nationwide search and interviews with multiple candidates. Mr. Rowe has also been appointed to Eyenovia's Board of Directors, increasing the Board to nine seats following recent appointments of Drs. Strahlman and Palanki as new independent directors, announced in July. Eyenovia's current Chief Exec

    7/27/22 8:00:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care